Indian pharma leaders seek faster trials, state-backed market for new drugs
· Business Today Mkts
Kiran Mazumdar-Shaw flags regulatory delays; Glenmark's Glenn Saldanha calls for reimbursement support for life-saving…
The analysis
Because the driver here is macro rather than company-specific, the read-through is to index-level positioning rather than to any single name — correlations tend to rise when the whole market faces the same signal.
Market context
- A market-wide development: it reaches beyond any single stock.
- Sectors in the story: Pharma & Healthcare.
Pharma & Healthcare
1M -0.6% · 3M -0.9%
Sector moves are the average of the stocks we track in each sector.
In this story
Related coverage
Nifty IT’s 18% rally may mark a durable leadership cycle; 35,000 next: LKP's Vatsal Bhuva
Bonus share: Just single issue with record date this week: Pharma firm's free shares with 68% returns since IPO; ratio
Cash rewards coming? PFC, CONCOR, RITES, to Sonata- These firms to announce dividend with Q2 results 2026 this week
Pharma company Gufic buys Lodha Avalon duplex in Juhu for ₹236 crore
Nifty Pharma index hits record high; Sun, Laurus, Zydus, Sai rally up to 6%